WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index.  The inclusion became effective at the close of market on Friday, May 31, 2024.  The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised o ...

Envoy Medical in Position to Leverage its Sensor Technology WHITE BEAR LAKE, MN, June 05, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today highlighted a recently published article in the Current Otorhinolaryngology Reports. The article, titled, "Fully Implanted Cochlear Implants," was authored by Dr. Eric Babajanian, Dr. James Dornhoffer, and Dr. Colin Driscoll from Mayo Clinic in Rochester, Minnesota. Authors describe it as a review of the current state of fully implante ...

We Are/DigitalVision via Getty Images Envoy Medical (NASDAQ:COCH) is a hearing device company for people with moderate to severe hearing loss. It is the only company that offers an FDA approved active fully implantable device, the Esteem Active Middle Ear implant. This device has lacked commercial success due to its Medicaid classification as a hearing aid, which is not eligible for coverage. Private insurance companies typically follow Medicaid reimbursement policies. Few people are capable or willing ...

Exhibit 99.1 Envoy Medical Reports First Quarter 2024 Results The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number - 001-40133 ENVOY MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 86-1369123 (State or other jurisdiction of (I.R ...

Envoy Medical公司 - 首席执行官Brent Lucas和首席财务官David R. Wells将在LD Micro Invitational XIV 2024上进行企业概况介绍[1] - Envoy Medical公司提供的重要安全信息可在其网站上找到[9] - Envoy Medical公司的前瞻性声明包括对其业务前景、生产力、未来运营改进和资本投资计划的期望，以及对Acclaim CI作为市场上第一个全植入式耳蜗植入装置的影响等内容[12] Acclaim Cochlear Implant - Acclaim Cochlear Implant是一种全植入式耳蜗植入装置，旨在解决严重至极重的感音神经性听力丧失问题[3][4] - Acclaim Cochlear Implant获得了美国食品和药物管理局（FDA）2019年的突破性设备认定[5] Esteem全植入式主动中耳植入装置 - Esteem全植入式主动中耳植入装置是唯一获得FDA批准的全植入式听力设备，适用于被诊断为中度至重度感音神经性听力丧失的成年人[7] - Esteem FI-AMEI听力植入装置不需要外部佩戴组件，也不需要放置在耳道中，提供真正的全天候听力[7]

Envoy Medical公司 - Envoy Medical公司在2023年完成了商业合并交易，并于2023年10月在纳斯达克交易所上市[2] - 公司从亿万富翁企业家Glen Taylor处获得了高达1000万美元的非可转换无担保债务融资[3] - Envoy Medical公司宣布新增四项专利，使公司总共拥有30项已颁发的美国专利、16项待批准的美国专利申请、12项已颁发的外国专利和28项待批准的外国和国际专利申请[5] Acclaim® Cochlear Implant - Acclaim® Cochlear Implant的早期可行性研究持续达到里程碑，所有三名植入患者在激活后十二个月的访问中仍然植入[4] - Acclaim® Cochlear Implant被美国食品和药物管理局（FDA）授予突破性设备认定[14] Esteem® Fully Implanted Active Middle Ear Implant（FI-AMEI） - Esteem® Fully Implanted Active Middle Ear Implant（FI-AMEI）继续努力解决全植入式活动中耳植入物（FI-AMEI）被错误分类为助听器的问题，并推出了跨党派的国会法案 - Hearing Device Coverage Clarification Act（H.R. 7254）[6] 财务状况 - ENVOY MEDICAL, INC.在2023年的净亏损为$29,908，较2022年的$15,923有所增加[25] - 在2023年，ENVOY MEDICAL, INC.的现金流量从经营活动中净使用了$17,654，较上一年的$8,805有所增加[25] - ENVOY MEDICAL, INC.在2023年通过融资活动获得的净现金为$21,845，较上一年的$8,092有所增加[26]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-40133 ENVOY MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 86-1369123 (State or other ju ...

Envoy Medical公司参加ROTH Conference - Envoy Medical公司将参加第36届ROTH Conference，将在2024年3月17日至19日在加州Dana Point的The Ritz Carlton举行[1] - 公司的首席财务官David R. Wells将在会议上与投资者和分析师进行一对一会议，讨论最近事件和临床试验的更新[2] Acclaim Cochlear Implant介绍 - 公司推出的全植入式Acclaim Cochlear Implant（Acclaim CI）被认为是首款全植入式耳蜗植入器，采用传感器捕捉声音，而不是麦克风[3] - Acclaim CI旨在解决严重至极重的感音神经性听力丧失问题，适用于被合格医生认定为合适候选人的成年人[4]

 Billionaire Entrepreneur Glen Taylor Commits to a 5-Year Facility to Support Company's upcoming FDA Clinical Trial for the Acclaim® Fully Implanted Cochlear Implant WHITE BEAR LAKE, Minnesota, March 04, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced the closing of up to a $10 million, five-year lending facility provided by existing investor and billionaire entrepreneur Glen ...